Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

12.90
+0.12000.94%
Volume:159.35K
Turnover:2.04M
Market Cap:1.34B
PE:-2.47
High:12.92
Open:12.82
Low:12.76
Close:12.78
Loading ...

Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock

Simply Wall St.
·
09 Jul

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Jul

Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital

TIPRANKS
·
08 Jul

RBC Cuts Price Target on Intellia Therapeutics to $25 From $30, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jul

Intellia Therapeutics Executive Makes Significant Stock Sale

TIPRANKS
·
04 Jul

Eliana Clark, EVP and Chief Technical Officer, Reports Disposal of Intellia Therapeutics Common Shares

Reuters
·
04 Jul

Director Jesse Goodman Reports Disposal of Common Shares in Intellia Therapeutics Inc

Reuters
·
03 Jul

Wedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
16 Jun

Intellia Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Jun

Intellia Therapeutics Announces Positive Phase 1 Trial Data

TIPRANKS
·
16 Jun

Intellia Therapeutics Announces Promising Phase 3 Trial Results for Lonvo-z, Plans for 2027 U.S. Launch

Reuters
·
16 Jun

Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks

MT Newswires Live
·
16 Jun

Intellia Therapeutics Inc. Conducted Annual Meeting of Stockholders

Reuters
·
13 Jun

Bernstein Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
06 Jun

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks
·
04 Jun

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Zacks
·
04 Jun

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks
·
04 Jun

Intellia Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
03 Jun

Intellia Therapeutics price target lowered to $54 from $74 at Canaccord

TIPRANKS
·
03 Jun

Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study

TIPRANKS
·
30 May